(1) the need for review of human subject regu-
lations specified in part 46 of title 45, Code of Fed-
eral Regulations (or successor regulations), and re-
lated guidance; 
(2) the modernization of such regulations and 
guidance to establish updated guidelines for reim-
bursement of out-of-pocket expenses of human sub-
jects, compensation of human subjects for time 
spent participating in the clinical trial, and incen-
tives for recruitment of human subjects; and 
(3) the need for updated safe harbor rules 
under section 1001.952 of title 42, Code of Federal 
Regulations (or successor regulations) and section 
1128B of the Social Security Act (commonly re-
ferred to as the Federal Anti-Kickback Statute (42 
U.S.C. 1320a–7b)) with respect to the assistance 
provided under this section. 
SEC. 4. PUBLIC AWARENESS AND EDUCATION CAMPAIGN. 
(a) NATIONAL CAMPAIGN.—The Secretary of Health 
and Human Services, acting through the Director of the 
National Institutes of Health and the Commissioner of 
Food and Drugs (referred to in this section as the ‘‘Sec-
retary’’) and in consultation with the stakeholders speci-
fied in subsection (e), shall carry out a national campaign 
to increase the awareness and knowledge of individuals in 
VerDate Sep 11 2014 
02:09 Jun 10, 2023
Jkt 039200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H3503.IH
H3503
pbinns on DSKJLVW7X2PROD with $$_JOB
the United States, including healthcare professionals, pa-
tients, and others, with respect to the need for diverse clin-
ical trials among the demographic groups identified pursu-
ant to section 2(a)(1). 
(b) REQUIREMENTS.—The national campaign con-
ducted under this section shall include— 
(1)(A) the development and distribution of writ-
ten educational materials; 
(B) the development and placing of public serv-
ice announcements that are intended to encourage 
individuals who are members of the demographic 
groups identified pursuant to section 2(b)(1)(A)(I) 
to seek to participate in clinical trials; and 
(C) the development of curricula for health care 
professionals on— 
(i) how to participate in clinical trials as 
an investigator; and 
(ii) how such professionals can enroll pa-
tients in trials; 
(2) such efforts as are reasonable and necessary 
to ensure meaningful access by consumers with lim-
ited English proficiency; 
(3) the development and distribution of best 
practices and training for recruiting underrep-
resented study populations, including a method for 
VerDate Sep 11 2014 
02:09 Jun 10, 2023
Jkt 039200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H3503.IH
H3503
pbinns on DSKJLVW7X2PROD with $$_JOB
sharing such best practices among clinical trial spon-
sors, providers, community-based organizations who 
assist with recruitment, and with the public; and 
(4) the conduct of focus groups to better under-
stand the concerns and fears of certain underrep-
resented groups who may be reluctant to participate 
in clinical trials. 
(c) HEALTH INEQUITIES.—In developing the national 
campaign under subsection (a), the Secretary shall recog-
nize and address— 
(1) health inequities among individuals who are 
members of the population groups specified in sec-
tion 2(b)(1)(A) with respect to access to care and 
participation in clinical trials; and 
(2) any barriers in access to care and participa-
tion in clinical trials that are specific to individuals 
who are members of such groups. 
(d) GRANTS.—The Secretary shall establish a pro-
gram to award grants to nonprofit private entities (includ-
ing community based organizations and faith commu-
nities, institutions of higher education eligible to receive 
funds under section 371 of the Higher Education Act of 
1965 (20 U.S.C. 1067q), national organizations that serve 
underrepresented populations, and community phar-
macies) to enable such entities— 
VerDate Sep 11 2014 
02:09 Jun 10, 2023
Jkt 039200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H3503.IH
H3503
pbinns on DSKJLVW7X2PROD with $$_JOB
(1) to test alternative outreach and education 
strategies to increase the awareness and knowledge 
of individuals in the United States, with respect to 
the need for diverse clinical trials that reflect the 
race, ethnicity, age, and sex of patients with the dis-
ease or condition being investigated; and 
(2) to cover administrative costs of such entities 
in assisting in diversifying clinical trials subject to 
section 2. 
(e) STAKEHOLDERS SPECIFIED.—The stakeholders 
specified in this subsection are the following: 
(1) Representatives of the Health Resources 
Services Administration, the Office on Minority 
Health of the Department of Health and Human 
Services, the Centers for Disease Control and Pre-
vention, and the National Institutes of Health. 
(2) Community-based resources and advocates. 
(f) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section 
$10,000,000 for each of fiscal years 2025 through 2028. 
SEC. 5. DEFINITIONS. 
In this Act: 
(1) CLINICAL TRIAL.—The term ‘‘clinical trial’’ 
means a research study in which one or more human 
subjects are prospectively assigned to one or more 
VerDate Sep 11 2014 
02:09 Jun 10, 2023
Jkt 039200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H3503.IH
H3503
pbinns on DSKJLVW7X2PROD with $$_JOB
interventions (which may include placebo or other 
control) to evaluate the effects of those interventions 
on health-related biomedical or behavioral outcomes. 
(2) SPONSOR.—The term ‘‘sponsor’’ has the 
meaning given such term in section 50.3 of title 21, 
Code of Federal Regulations (or successor regula-
tions). 
Æ 
VerDate Sep 11 2014 
02:09 Jun 10, 2023
Jkt 039200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6301
E:\BILLS\H3503.IH
H3503
pbinns on DSKJLVW7X2PROD with $$_JOB